Faridzadeh Arezoo, Yadegari Yaser, Bakhshaee Mahdi, Kabiri Mona, Mohammadi Mozhgan, Khoshkhui Maryam, Jabbari Azad Farahzad
Immunology Research Center Mashhad University of Medical Sciences Mashhad Iran.
Department of Immunology and Allergy, School of Medicine Mashhad University of Medical Sciences Mashhad Iran.
Health Sci Rep. 2023 Oct 3;6(10):e1571. doi: 10.1002/hsr2.1571. eCollection 2023 Oct.
Allergic rhinitis (AR) is a prevalent chronic disease affecting a significant portion of the global population. The substantial economic burden associated with treating AR necessitates the exploration of alternative therapies. Probiotics have gained attention due to their availability, minimal adverse effects, and cost-effectiveness. The present study aims to investigate the role of synbiotics as adjunctive agents in the treatment of AR when added to standard treatment.
Thirty patients with persistent allergic rhinitis (PAR) were randomly assigned to receive routine diet therapy plus synbiotics or routine diet therapy plus placebo per day for 4 months. The data analysis was conducted using SPSS Version 20.
This study revealed a notable difference in immunoglobulin (Ig)E levels between the placebo and synbiotics groups ( = 0.035) following the intervention. Although a statistically significant difference ( = 0.039) was observed in the changes before and after the intervention (synbiotics and placebo) in the SNOT22 questionnaire, this finding was not observed for the MiniRQLQ questionnaire. For the MiniRQLQ questionnaire, the within-group analysis showed significant changes in activity variables ( = 0.023), ocular symptoms ( = 0.036), and practical problems ( = 0.043) exclusively in the synbiotics group. Additionally, changes in nasal symptoms were observed in both synbiotics ( = 0.006) and placebo ( = 0.007) groups.
This study suggests that synbiotics supplementation for 4 months can impact IgE levels compared with placebo in individuals with PAR, while also exhibiting positive effects on symptomology.
过敏性鼻炎（AR）是一种常见的慢性疾病，影响着全球相当一部分人口。与治疗AR相关的巨大经济负担使得探索替代疗法成为必要。益生菌因其可得性、不良反应少和成本效益高而受到关注。本研究旨在探讨合生元作为辅助剂添加到标准治疗中时在AR治疗中的作用。
30例持续性过敏性鼻炎（PAR）患者被随机分配，每天接受常规饮食疗法加合生元或常规饮食疗法加安慰剂，为期4个月。使用SPSS 20版进行数据分析。
本研究显示，干预后安慰剂组和合生元组之间的免疫球蛋白（Ig）E水平存在显著差异（P = 0.035）。虽然在SNOT22问卷中干预前后（合生元和安慰剂）的变化观察到有统计学显著差异（P = 0.039），但在MiniRQLQ问卷中未观察到这一结果。对于MiniRQLQ问卷，组内分析显示仅在合生元组中，活动变量（P = 0.023）、眼部症状（P = 0.036）和实际问题（P = 0.043）有显著变化。此外，合生元组（P = 0.006）和安慰剂组（P = 0.007）的鼻部症状均有变化。
本研究表明，与安慰剂相比，PAR患者补充合生元4个月可影响IgE水平，同时对症状也有积极影响。
